Brief: Centessa Pharmaceuticals Announces Additional 18-Months Of Continued Treatment Data From Open-Label Extension (Ole) Of Phase 2A Study Of Serpinpc For Hemophilia

Centessa Pharmaceuticals

10/12/2022 21:56

Dec 10 (Reuters) - Centessa Pharmaceuticals Plc
 260y.F :
    * CENTESSA PHARMACEUTICALS ANNOUNCES ADDITIONAL 18-MONTHS OF
CONTINUED TREATMENT DATA FROM OPEN-LABEL EXTENSION (OLE) OF
PHASE 2A STUDY OF SERPINPC FOR HEMOPHILIA
    * CENTESSA PHARMACEUTICALS - ORAL PRESENTATION  HIGHLIGHTS
CONTINUED FAVORABLE SAFETY, TOLERABILITY PROFILE, SUSTAINED
LONG-TERM EFFICACY RESULTS
    * NO THROMBOEMBOLIC EVENTS OR TREATMENT-RELATED SUSTAINED
ELEVATIONS OF D-DIMER OBSERVED
    * 93% REDUCTION IN MEDIAN ABR FOR BOTH ALL-BLEEDS AND
SPONTANEOUS
JOINT BLEEDS IN HIGHEST DOSE TESTED

Source text for Eikon:  ID:nGNE6yVSqr 
Further company coverage:  260y.F 
 ((Reuters.Briefs@thomsonreuters.com;))